Trial Profile
Phase III Randomized Trial Comparing Short Course Androgen Deprivation Therapy and Ultra-Hypofractionated SBRT Versus SBRT Alone For Intermediate Prostate Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 16 Aug 2023 Status changed from active, no longer recruiting to completed.
- 01 Mar 2022 Planned End Date changed from 1 Feb 2022 to 1 Feb 2024.
- 01 Mar 2022 Planned primary completion date changed from 1 Feb 2022 to 1 Feb 2024.